Related Experiment Video

Updated: Jun 23, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

[Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment]

Valentin Daguerre1, Carolyne Croizier2

  • 1Hématologie clinique adulte et thérapie cellulaire, CHU de Saint-Étienne, université Jean-Monnet de Saint-Étienne, Saint-Étienne, France.

Bulletin Du Cancer
|June 14, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Anti-CD3/CD20 antibodyAnticorps anti-CD3/CD20Anticorps monoclonal bispécifiqueBispecific monoclonal antibodyDiffuse large-cell B lymphomaGlofitamabImmunotherapyImmunothérapieLymphome B diffuse à grandes cellules

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Related Concept Videos